血清SP-A、SP-D在特发性肺间质纤维化疾病进展过程中的临床意义  

Clinical significance of serum SP-A and SP-D in disease development of idiopathic pneumonia fibrosis

作　　者：尹虹雷[1] 尹世琦[2] 刘涛[1] 林庆艳[1] 崔晓媛[1] 唐正梁[1] 

机构地区：[1]黑龙江省医院南岗院区呼吸内科,黑龙江哈尔滨150001 [2]黑龙江省电力医院内二科,黑龙江哈尔滨150002

出　　处：《中国现代医生》2015年第36期13-16,共4页China Modern Doctor

基　　金：黑龙江省科技计划项目(GC08C422)

摘　　要：目的 研究血清SP-A、SP-D浓度在特发性肺间质纤维化（idiopathic pneumonia fibrosis,IPF）患者疾病发展过程中的临床意义。方法 将受试者分为4组,A组为肺泡炎症组（ground-glass opacity,GGO）,B组为网格类型组（parenchymal collapse-opacity,PCO）,C组为蜂窝肺组（honeycomb lung）,D组为正常对照组,每组各18例受试者。采用酶联免疫吸附法（enzyme linked immunosorbent assay,ELISA）检测4组受试者血清SP-A、SP-D表达水平。进一步将A组中18例受试者按其HRCT显像分为阶段1（累及2个肺区）,阶段2（累及2-4个肺区）,阶段3（累及4个肺区以上）。结果 4组受试者血清SP-A、SP-D的表达水平运用单因素方差分析比较,差异有统计学意义。当患者HRCT显示为GGO时,其病变占肺面积的大小不同,血清中SP-A的表达水平与病变范围密切相关,差异具有统计学意义。结论 SP-A、SP-D伴随IPF病程进展而变化,联合监测是判断疾病严重程度的有价值的无创性指标之一。Objective To explore the clinical significance of serum SP-A and SP-D in disease development of idiopathic pneumonia fibrosis（IPF）.Methods The subjects were divided into four groups,group A was ground-glass opacity group（GGO）,group B was parenchymal collapse-opacity group（PCO）,group C was honeycomb lung group,and group D was healthy control group,each with 18 subjects.The expression levels of serum SP-A and SP-D were detected by enzyme linked immunosorbent assay（ELISA）.The 18 subjects in group A were further divided into stage 1（involving 2lung regions）,stage 2（involving 2 to 4 lung regions）,and stage 3（involving more than 4 lung regions） based on their HRCT image.Results Compared by one-way analysis of variance,the serum SP—A and SP-D expression levels in four groups showed significant difference.When the HRCT indicating GGO,the occupied region of lesion on lung was various and the expression level of serum SP-A was closely related to the lesion size,which was statistically significant.Conclusion The levels of SP-A and SP-D change along with the development of IPF disease course.Combined monitoring is a valuable noninvasive method to judge the severity of disease.

关 键 词：特发性肺间质纤维化 SP-A SP-D 无创检测 病情评估 

分 类 号：R563.9[医药卫生—呼吸系统]